Japanese Journal of Clinical Oncology Advance Access originally published online on June 1, 2005
Japanese Journal of Clinical Oncology 2005 35(6):293-301; doi:10.1093/jjco/hyi088
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Foundation for Promotion of Cancer Research
Review Article |
Diagnostic and Therapeutic Applications of Epigenetics
Carcinogenesis Division, National Cancer Center Research Institute, Tokyo, Japan
For reprints and all correspondence: Toshikazu Ushijima, Carcinogenesis Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan. E-mail: tushijim{at}ncc.go.jp
Received February 24, 2005; accepted April 11, 2005
Epigenetic abnormalities, such as aberrant methylation of CpG islands, are inherited over cell divisions, and play important roles in carcinogenesis. Aberrant methylation of CpG islands specific to tumor cells can be used as a marker to detect cancer cells or cancer-derived DNA, taking advantage of the high sensitivity of methods to detect aberrant methylation. Methylations of specific genes or methylation patterns of groups of genes were found to be associated with responses to chemotherapeutics and prognosis. Methylation in non-cancerous tissues is now attracting attention as a tumor risk marker, and is emerging as a target for cancer prevention. Epigenetic alterations are potentially reversible. The use of DNA demethylating agents has turned out to be effective for hematological malignancies, and is being tested in solid tumors. Histone deacetylase inhibitors and methods for gene-specific epigenetic modification are being developed. Application of epigenetics to cancer diagnostics and therapeutics, and possibly to cancer prevention, is coming into clinics.
Key Words: epigenetics • CpG island • DNA methylation • tumor marker • cancer therapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Kageyama, K. Shinmura, H. Yamamoto, M. Goto, K. Suzuki, F. Tanioka, T. Tsuneyoshi, and H. Sugimura Fluorescence-labeled Methylation-sensitive Amplified Fragment Length Polymorphism (FL-MS-AFLP) Analysis for Quantitative Determination of DNA Methylation and Demethylation Status Jpn. J. Clin. Oncol., April 1, 2008; 38(4): 317 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kholod, J. Boniver, and P. Delvenne A New Dimethyl Sulfoxide-Based Method for Gene Promoter Methylation Detection J. Mol. Diagn., November 1, 2007; 9(5): 574 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Furuta, Y. Nobeyama, Y. Umebayashi, F. Otsuka, K. Kikuchi, and T. Ushijima Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res., June 15, 2006; 66(12): 6080 - 6086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Coleman and A. G. Rivenbark Quantitative DNA Methylation Analysis: The Promise of High-Throughput Epigenomic Diagnostic Testing in Human Neoplastic Disease J. Mol. Diagn., May 1, 2006; 8(2): 152 - 156. [Full Text] [PDF]
|
|